-
公开(公告)号:US20120184559A1
公开(公告)日:2012-07-19
申请号:US13362833
申请日:2012-01-31
IPC分类号: A61K31/4965 , A61K31/4439 , A61K31/425 , C12N9/99 , A61K31/27
CPC分类号: C07D277/30 , A61K31/426 , A61K31/427 , A61K45/06 , C07C53/18 , C07D213/30 , C07D231/12 , C07D233/64 , C07D263/32 , C07D277/24 , C07D277/38 , C07D277/587 , C07D333/16 , C07D417/04
摘要: Novel compounds of formula 1 or a pharmaceutically acceptable salt thereof inhibit cytochrome P450 monooxygenase.
摘要翻译: 新的式1化合物或其药学上可接受的盐抑制细胞色素P450单加氧酶。
-
公开(公告)号:US20120083490A1
公开(公告)日:2012-04-05
申请号:US13315137
申请日:2011-12-08
申请人: Larry L. Klein , Hui-Ju Chen , Ming C. Yeung , Charles A. Flentge , John T. Randolph , Peggy P. Huang , Douglas K. Hutchinson , Dale J. Kempf
发明人: Larry L. Klein , Hui-Ju Chen , Ming C. Yeung , Charles A. Flentge , John T. Randolph , Peggy P. Huang , Douglas K. Hutchinson , Dale J. Kempf
IPC分类号: A61K31/5355 , C07D417/12 , A61K31/426 , A61K31/427 , C12N9/99 , A61K31/4439 , A61K31/513 , C07D417/14 , A61K31/496 , A61K31/5377 , A61K31/4535 , A61P31/12 , A61P31/14 , A61P43/00 , C07D277/30
CPC分类号: A61K31/5377 , A61K31/4164 , A61K31/4178 , A61K31/4439 , A61K31/4525 , A61K31/496 , A61K31/506 , A61K45/06 , C07D213/79 , C07D277/24 , C07D277/30 , C07D277/593 , C07D417/12
摘要: The present invention features compounds of formula I or pharmaceutically acceptable salts, solvates or prodrugs thereof, and methods of using the same to inhibit the metabolizing activities of CYP enzymes. The present invention also features methods of using these compounds, salts, solvates or prodrugs to improve the pharmacokinetics of drugs that are metabolized by CYP enzymes.
摘要翻译: 本发明的特征在于式I化合物或其药学上可接受的盐,溶剂合物或前药,以及使用该化合物抑制CYP酶代谢活性的方法。 本发明还涉及使用这些化合物,盐,溶剂合物或前药来改善由CYP酶代谢的药物的药代动力学的方法。
-
公开(公告)号:US5543505A
公开(公告)日:1996-08-06
申请号:US213053
申请日:1993-03-15
IPC分类号: A61K38/00 , C07H3/06 , C07H17/04 , C07K9/00 , C07K14/765 , C07H15/00 , C07H15/06 , C07H17/00 , C07K1/00
CPC分类号: C07K14/765 , C07H17/04 , C07H3/06 , C07K9/00 , A61K38/00
摘要: The present invention provides a compound having the structure: ##STR1## wherein A is selected from the group consisting of (i) an amino acid bearing an .omega.-amino group or an .omega.--(C.dbd.O)-- group, (ii) an amino acid residue of a peptide, which residue bears an .omega.-amino group or an .omega.-(C.dbd.O)-- group, and (iii) an amino acid residue of a protein, which residue bears an .omega.-amino group or an .omega.-(C.dbd.O)-- group; wherein R.sub.1 is H, OH, NH.sub.2 or NHR.sub.4, where R.sub.4 is SO.sub.2 Ph, a linear or branched chain alkyl or acyl group, or an aryl group; wherein M is a saccharide wherein n is an integer from 0 to 18, and where n is greater than 1, each M is independently the same or different; wherein p is either 0 or 1; wherein R.sub.2, R.sub.3, R.sub.5 and R.sub.6 are independently the same or different and are H or OH, with the proviso that R.sub.2 and R.sub.3 are not both OH, and R.sub.5 and R.sub.6 are not both OH; wherein X and Y are independently the same or different and are H.sub.2 or O; and wherein k is an integer greater than or equal to 1, with the proviso that when A is an amino acid bearing an .omega.-amino group or an .omega.-(C.dbd.O)-- group, k is equal to 1.
摘要翻译: 本发明提供具有以下结构的化合物:其中A选自(i)具有ω-氨基或ω-(C = O) - 基团的氨基酸 ,(ii)肽的氨基酸残基,该残基具有ω-氨基或ω-(C = O) - 基团,和(iii)蛋白质的氨基酸残基,该残基具有ω- 氨基或ω-(C = O) - 基团; 其中R 1是H,OH,NH 2或NHR 4,其中R 4是SO 2 Ph,直链或支链烷基或酰基或芳基; 其中M是糖,其中n是0至18的整数,并且其中n大于1,每个M独立地相同或不同; 其中p是0或1; 其中R2,R3,R5和R6独立地相同或不同,为H或OH,条件是R2和R3不同时为OH,R5和R6不同时为OH; 其中X和Y独立地相同或不同,为H 2或O; 并且其中k是大于或等于1的整数,条件是当A是具有ω-氨基或ω-(C = O) - 基团的氨基酸时,k等于1。
-
公开(公告)号:US07517876B2
公开(公告)日:2009-04-14
申请号:US11363377
申请日:2006-02-27
申请人: Larry L. Klein , Peggy P. Huang , John T. Randolph , Douglas K. Hutchinson , Ming C. Yeung , Charles A. Flentge
发明人: Larry L. Klein , Peggy P. Huang , John T. Randolph , Douglas K. Hutchinson , Ming C. Yeung , Charles A. Flentge
IPC分类号: C07D285/26 , A61K31/549
CPC分类号: C07D471/04 , C07D285/24 , C07D285/30 , C07D417/12
摘要: Compounds having the formula are hepatitis C (HCV) polymerase inhibitors. Also disclosed are compositions and methods for inhibiting hepatitis C (HCV) polymerase, processes for making the compounds, and synthetic intermediates employed in the processes.
摘要翻译: 具有下式的化合物是丙型肝炎(HCV)聚合酶抑制剂。 还公开了用于抑制丙型肝炎(HCV)聚合酶,制备化合物的方法和在该方法中使用的合成中间体的组合物和方法。
-
-
-